Measuring quality in psoriasis: Early experiences with the MIPS 410 quality measure—A cross-sectional study - 14/04/23

| Funding sources: Dr Secrest is supported by research grants from the National Psoriasis Foundation and a Dermatology Foundation Public Health Career Development Award. The authors received no financial support for this research project, its authorship, and/or publication. |
|
| Disclosure: Dr Callis Duffin has been a consultant or investigator for Amgen, AbbVie, Janssen, Celgene, Novartis, Lilly, Ortho Dermatologics, Stiefel, Bristol Myers Squib, Pfizer, UCB, Sienna, and Boehringer Ingelheim and is a nonpromotional speaker for Novartis. Dr Taliercio, Ms Langner, and Dr Secrest have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved under IRB 00076927. |
Vol 88 - N° 5
P. 1119-1121 - mai 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
